Radically extended
healthspan for all
34+ million lives and counting
Healthspan is the period of life spent in good health, generally free from disease and disability.
Early stage healthtech venture capital fund investing in impactful health technology startups globally.
Our Mission
Healthtech investment is the key to extending healthspan for all.
Traditional healthcare is slow and ineffective. To radically extend healthspan for all, we believe healthcare needs to be exponentially more efficient and effective. Healthtech is leading this change.
Healthtech leverages technology to amplify the current health system. It connects and extends traditional health sectors with adjacent non-health sectors that easily reach billions.
Why Founders Choose Us
More Than Capital. A Partner.
We don't just write cheques. We provide the clinical, regulatory, and commercial expertise needed to navigate the complex healthcare landscape.
Specialists, Not Generalists
We are clinicians, scientists, and operators. We understand the science, the regulatory pathways (FDA/CE), and the clinical workflows required for adoption.
Global Commercialisation
Healthcare is local, but innovation is global. We bridge Asian, European, and US markets, helping portfolio companies expand internationally from day one.
Hands-On Validation
We help structure clinical trials and pilot programs through our network of hospital partners. We de-risk the path from bench to bedside.
Our partners have led digital transformations at top-tier firms and founded successful healthtech startups. We've sat in your seat.
Changemakers. Not just investors.
We seek and support visionary, passionate, and persistent founders who are creating transformative healthtech companies today that shape our vision of tomorrow.
Active Expertise
Experienced healthtech operators that actively partner with founders crossing the chasm from early to growth stage.
Global Ecosystem
Access to Verge's global network of leading companies, investors, and institutions to help your company scale.
Portfolio Synergies
Collaboration with our extended portfolio on R&D, commercial distribution, and clinical trials.
Investment Scope
Where we invest in global healthtech.
We invest in & help scale:
Technologies that solve large unmet needs in health and platforms that can reach millions.
AI and Data Analytics
Solutions that use artificial intelligence and/or data analysis techniques to extract actionable and valuable insights and patterns within healthcare data.
Next Gen Diagnostics
Advanced diagnostic tools incorporating cutting-edge detection technologies, algorithms and/or novel biomarkers, to diagnose and/or monitor diseases earlier.
Breakthrough Smart Devices
Highly innovative wearable or portable devices that incorporate smart technologies to monitor, diagnose, or treat health conditions.
Digital Health Platforms
Online platforms that facilitate various health services such as telemedicine, remote patient monitoring, chronic disease management, and patient engagement.
Digital Therapeutics
Digital systems or software used as therapeutic interventions for treating, managing, or preventing a specific health condition.
Healthcare SaaS
Software-as-a-Service platforms specifically designed for healthcare that do not directly face patients, such as EHR, billing, and inventory management.
Global Footprint
Global healthtech investment has no borders.
34,418,954 lives impacted across our global portfolio.
36
Companies
49
Countries
22
LMIC Markets
Portfolio
Healthtech startups backed by Verge.

Arogga
Vertically integrated digital pharmacy in Bangladesh with proprietary fulfillment infrastructure delivering authentic medications

Bot MD
Chat-first automation platform that embeds AI agents into messaging apps to digitise patient engagement workflows

BrainCapture
Low-cost, high quality, smartphone pairable EEG amplifier with a novel cap that allows for remote neurology diagnostics

CareLoop Health
Predictive digital therapeutics for people living with serious mental illness, starting with psychosis
ChestPal
The world’s most affordable and intelligent digital stethoscope for lung sounds (and soon heart)

CuboAi
Proactive AI for your baby's sleep, safety, health, and memories
Insights
Latest news & updates
Finland Launches Eir Accelerator, a Dedicated Women’s Health Startup Program
Verge HealthTech Fund is a key member of the international investor network backing the newly launched Eir Accelerator, a dedicated women’s health startup program established by the Women’s Health Hub Finland. Based in Turku, this structured six-month acceleration program supports early-stage femtech and women's health startups from the Nordics, wider Europe, and beyond by helping them generate clinical evidence, navigate European and U.S. regulations, and build vital partnerships with major pharma companies like Bayer, Organon, and Orion.
ThinkMD Wins the Future Health Challenge Grand Prize
ThinkMD.ai has been awarded the USD 200,000 grand prize as the winner of the Future Health Challenge, organized in collaboration with MIT Solve. The award was presented at the World Health Assembly in Geneva. ThinkMD develops mobile clinical decision-support tools that empower frontline healthcare workers to deliver faster, more informed triage, treatment, and referral services. Beyond direct patient care, the platform translates routine care encounters into real-time population health data. In Zambia, symptom patterns recorded on the platform warned of an impending cholera outbreak. Currently, the innovation is utilized by more than 9,000 frontline workers across 885 facilities. Co-founder Dr. Jackie Rabec shared that the tool aims to address the global shortage of 15 million healthcare workers. Moving forward, ThinkMD plans to scale its operations into Nigeria, Rwanda, and Somalia, deliver its health intelligence portal, and validate its next-generation multimodal flexi interface.
Femtech World reveals startup of the year shortlist
Femtech World has announced the three finalists for the Startup of the Year Award, sponsored by Future Fertility. The winner will be determined by a representative of the sponsor and announced at a virtual ceremony on June 19, 2026. The shortlisted companies are: Hello Inside: An AI health company that translates daily metabolic signals into health outcomes. Across four years and over 12,000 validated metabolic profiles, 75% of users improved at least one symptom within 90 days, losing an average of 4 kg in three months. In a clinical study with Alisa Vitti’s Flo Living, 91.9% of participants reported reduced PMS burden within 60 days. OvartiX: A drug discovery firm powered by its machine-learning platform, OmiXX, which uses ovarian cellular models and human multi-omics data. Its lead candidate, OVX001, is designed to preserve 80% to 95% of ovarian follicles during chemotherapy or radiotherapy to prevent medically induced menopause in young female cancer patients. U-Ploid: An early-stage biotechnology startup targeting age-related chromosomal errors in eggs to directly improve oocyte quality for women undergoing IVF and egg freezing.
Our Team
Seasoned investors.
Former operators.
Ready to build
the future?
We are looking for visionary founders solving the hardest problems in healthcare. If that's you, we want to hear from you.